Boston Scientific Corp (BSX)vsEquinor ASA ADR (EQNR)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
EQNR
Equinor ASA ADR
$40.46
+1.28%
ENERGY · Cap: $103.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 428% more annual revenue ($105.98B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 4.8%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
EQNR
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
-116.7%
Fair Value
$13.19
Current Price
$40.46
$27.27 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 21.4%
Areas to Watch
Premium valuation, high expectations priced in
4.8% margin — thin
Weak financial health signals
Expensive relative to growth rate
Revenue declined 5.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : EQNR
The strongest argument for EQNR centers on Market Cap, Price/Book, Operating Margin.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a growth stock while EQNR is a value play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.70 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 45/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?